There are currently no specific tariffs or quotas on pharmaceutical imports.
However, on April 16, 2025, the secretary of commerce initiated a Section 232 investigation into whether pharmaceutical imports into the U.S. threaten to impair national security.
Interested parties are invited to submit comments by May 7, 2025.
This investigation will assess the national security risks related to imports of pharmaceuticals and pharmaceutical ingredients, including finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients, and key starting materials, and derivative products of those items.
Within 270 days, the secretary of commerce will submit a report to the president with findings and recommendations on actions to mitigate any threats, including potential tariffs, export controls, or incentives to increase domestic production.
ST&R offers a three-pronged approach for avoiding, mitigating, and/or recovering these and other tariffs. For more information on which of these strategies might be most effective for your business, please contact ST&R.
Official Documents